Press ReleasesSTENOCARE Comments On The Business Perspective Of Its Danish...

STENOCARE Comments On The Business Perspective Of Its Danish Indoor Cultivation Facility

-

Following the completion of the Danish facility upgrade, STENOCARE has shared three video tours from inside the facility. The tours demonstrate how the indoor facility is created as a building inside a building to optimize control of the climate and minimize potential risk of contamination. This is critical to be able to supply pharma-grade materials for medical cannabis products and to comply with the strict requirements from the medicine agencies.

STENOCARE explains that with the completion of their Danish indoor cultivation facility, the Company now has capacity to cover its expected supply needs for the next 4-5 years, corresponding to potential annual commercial value of DKK 150 mill from the facility alone. This assessment does not include the potential for additional commercial value from imported products.

Full control over product supply: The indoor cultivation facility is in operation today and requires no additional major investments to deliver premium quality medical cannabis materials. The facility is designed and able to cover STENOCARE’s entire capacity needs for the next 4-5 years – even if it is decided not to leverage capacity from STENOCARE’s product suppliers. This means that the Company has complete control of the supply situation, of course subject to having the necessary approvals and licenses.

Capacity to create a large European market leader: Based upon a continuation of the current market price levels for medical cannabis oil products, and assuming production is at full capacity, then the potential annual commercial value from the STENOCARE’s facility alone corresponds to a value of around DKK 150 million. Please notice that this should not be seen as a forecast or guidance for 2022 or 2023.

Agile and designed to scale: Most European markets are in their infancy and will only be able to generate small scale demand in the near term. At the same time, most industry experts agree that STENOCARE’s European home market will become the world’s biggest market for medical cannabis. In anticipation of this built up of demand, the indoor facility has been uniquely designed to cope with anything from small orders to large consistent supply. Also, with its strategic suppliers, STENOCARE is able to adapt to market growth beyond its own cultivation facility and will be able to offer a broad product portfolio for patient’s treatment.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you